Psilocybin Is Entering State-Regulated Treatment Programs. Has the Science Caught Up?
As more states create pathways for supervised psilocybin use, and a psilocybin medicine moves through FDA review, important questions remain about its effectiveness, safety, and the quality of the research supporting it.
By Izabella Alpert, PMHNP-BC · Research and legal information checked October 13, 2026
Psilocybin, the psychoactive compound found in certain mushrooms, has attracted considerable attention for its potential to treat depression and other psychiatric conditions. Research findings have been encouraging, some states have moved forward with legal access to supervised psilocybin experiences, and a psilocybin medicine is now under FDA review.
Oregon was the first state to create regulated psilocybin services, approving Measure 109 in 2020. Colorado followed with Proposition 122 in 2022. New Mexico enacted its Medical Psilocybin Act in 2025. The law requires the program to be in place by December 31, 2027, and the state has said it aims to begin serving its first patients by the end of 2026.
These developments represent a significant change in how psychedelic substances are being approached in the United States. They also make it worth looking closely at how much scientific evidence we actually have.
The Early Research Behind Psilocybin Treatment
When Oregon voters approved psilocybin services in 2020, much of the available clinical research involved relatively small groups of participants.
A 2016 Johns Hopkins study involving 51 patients with life-threatening cancer found that psilocybin, administered with psychological support, reduced depression and anxiety. A separate study at New York University involving 29 patients reported similarly promising findings. Both were randomized crossover studies, meaning participants received both treatments at different points in the study. The Hopkins trial compared higher and very low psilocybin doses; the NYU trial used niacin as its comparison. [1, 2]
Around the same time, researchers at Imperial College London conducted an early study of psilocybin for treatment-resistant depression. Participants experienced improvements, but the study included only 12 people and had no placebo group. [3]
These were meaningful early findings, but they were not definitive evidence of effectiveness. Small studies can identify promising treatments, yet they cannot reliably establish how well those treatments will work in larger, more diverse patient populations.
In 2021, the Imperial College group published a randomized trial comparing psilocybin with escitalopram, a commonly prescribed antidepressant, in 59 adults with moderate to severe major depression. On the trial's primary measure of depressive symptoms at six weeks, the difference between the two treatments was not statistically significant. Several secondary measures favored psilocybin, but the study was not designed to draw firm conclusions from them. [4]
By the time Colorado voted in November 2022, larger randomized research had emerged, including a trial of 233 participants with treatment-resistant depression published that month. The scientific foundation was growing, although important questions remained unanswered.
Findings From Larger Clinical Trials
One of the most significant studies was published in The New England Journal of Medicine in 2022. Researchers enrolled 233 adults with treatment-resistant depression and randomly assigned them to receive 25 mg, 10 mg, or 1 mg of psilocybin, accompanied by psychological support. [5]
At three weeks, participants receiving 25 mg experienced a significantly greater reduction in depressive symptoms than those receiving 1 mg. The 10 mg dose did not show the same statistically significant advantage.
The trial did not establish that the advantage seen at three weeks was sustained through 12 weeks. Adverse events were common, and suicidal ideation, suicidal behavior, or self-injury occurred in all dose groups. These events require attention, but their occurrence alone does not establish that psilocybin caused them.
A separate randomized study published in JAMA in 2023 included 104 adults with major depressive disorder. Participants received either 25 mg of psilocybin or 100 mg of niacin, a form of vitamin B3 used as an active placebo. Both groups received psychological support. [6]
The psilocybin group experienced significantly greater improvement in depressive symptoms over six weeks. These findings suggest that psilocybin may have meaningful antidepressant effects. They also highlight the need for larger studies that can clarify long-term benefits, relapse rates, and safety.
Phase 3 Trials and the Path to FDA Review
The largest psilocybin trials so far are two Phase 3 studies of COMP360, a synthetic psilocybin formulation developed by Compass Pathways for treatment-resistant depression. Both trials reported meeting their primary endpoints at six weeks. In July 2026, the company reported 26-week results from the second trial, COMP006, which enrolled nearly 600 participants and compared two doses of 25 mg, 10 mg, or 1 mg given three weeks apart. [7]
These results are promising, but they should be read with care. Most of the detail so far comes from company announcements rather than full peer-reviewed publications. The company reported that 39% of participants in the 25 mg group had at least a 25% reduction in depression scores by week six and, on average, maintained that response through week 26. A 25% reduction is a lower bar than the 50% reduction commonly used to define treatment response in depression research, and it is not the same as remission. [7]
On April 18, 2026, President Trump signed an executive order directing federal agencies to speed the review of psychedelic treatments for serious mental illness. Days later, the FDA awarded national priority vouchers, which can shorten review time, to Compass's psilocybin program for treatment-resistant depression and to the Usona Institute's psilocybin program for major depressive disorder. Compass has said it expects to complete its new drug application in late 2026 and, if the FDA approves it and the DEA reschedules the drug, to launch in the first half of 2027. [8, 9]
A priority voucher speeds the review process. It does not lower the evidence standard, and it is not approval.
The Problem With Placebo-Controlled Psychedelic Research
One of the greatest challenges in psychedelic research is maintaining blinding.
In a conventional medication trial, participants may not know whether they received an active medication or placebo. This helps researchers distinguish the effects of the medication from improvements related to expectations.
With psilocybin, maintaining that uncertainty is considerably more difficult. A 25 mg dose typically produces noticeable changes in perception, emotional experience, and consciousness. Even participants who have never used psychedelics may recognize that they received the active substance.
Some researchers use niacin as an active placebo because it can cause flushing, warmth, and tingling. It does not reproduce the psychedelic experience. Other trials, including the Phase 3 COMP360 studies, compare a full dose with a very low dose of psilocybin, which faces the same challenge.
A Swedish randomized, double-blind trial published in May 2026 illustrates this problem. It included 35 participants with recurrent major depression: 17 received 25 mg of psilocybin and 18 received 100 mg of niacin. Both groups received five psychotherapeutic support sessions. Prior psychedelic use was an exclusion criterion, yet participants still recognized which treatment they had received. [10]
The primary outcome favored psilocybin at day eight. At six weeks, about 53% of participants receiving psilocybin were in remission, compared with about 6% in the niacin group. At one year, psilocybin remission remained at about 53%, but the niacin group had risen to about 41%, and the difference in clinician-rated depression scores was no longer statistically significant.
Blinding was weak. At the one-year assessment, 16 of 17 psilocybin participants and all 16 niacin participants who answered correctly identified their treatment. Assessing clinicians also guessed assignments above chance.
This matters because expectations can influence how participants experience and report their symptoms. Clinicians' expectations may also affect assessments. The failure of blinding does not mean that psilocybin's antidepressant effects are simply placebo effects. It means researchers have greater difficulty determining how much improvement can be attributed specifically to the drug.
The same concern has shaped regulatory decisions. In 2024, the FDA declined to approve MDMA-assisted therapy for PTSD, and difficulty maintaining blinding was among the concerns raised during its review.
Long-Term Safety and Who Was Studied
Another important limitation is the relatively short follow-up period in many psychedelic trials.
Some studies report improvements lasting several months, the Swedish trial followed participants for a year, and the Phase 3 COMP360 trials are following participants for up to a year. Still, we have limited information about repeated administration, long-term psychiatric outcomes, and uncommon adverse reactions.
Most trials also use carefully selected participants. People with psychotic disorders, bipolar disorder, or certain other psychiatric risk factors are often excluded. Findings from controlled research settings cannot automatically be generalized to everyone seeking treatment.
Psychedelic experiences can be psychologically challenging. Anxiety, fear, confusion, and difficult emotional reactions may occur during or after administration. In the Swedish trial, two psilocybin participants experienced persistent severe anxiety requiring medical attention; no serious adverse events were judged drug-related. [10]
These risks deserve the same attention as the potential benefits.
Legal Access Is Not the Same as FDA Approval
Oregon and Colorado have established regulated frameworks for supervised psilocybin access. These frameworks differ from ordinary prescription treatment, and the rules are not identical across states.
Oregon: Adults 21 and older can access psilocybin services at licensed service centers with licensed facilitators. A psychiatric diagnosis, prescription, or medical referral is not required. Oregon describes these services as a health and wellness option, and facilitators complete state-approved training and licensing but are not required to be health care providers. A preparation session is required, and integration sessions must be made available afterward. For more detail, read Oregon Psilocybin Services: What to Know, and Where Integration Fits. [11]
Colorado: Its regulated natural medicine framework provides supervised services through licensed facilitators and healing centers for adults 21 and older. Separately, Colorado law allows adults 21 and older to possess, grow, and share certain natural medicines for personal use without payment. Those personal-use provisions should not be confused with the licensed-service framework. [12]
New Mexico: The Medical Psilocybin Act establishes a medical program for qualifying conditions, including treatment-resistant depression, PTSD, substance use disorders, and end-of-life care. Unlike Oregon and Colorado, patients must have a qualifying diagnosis, and services are delivered within a medical program rather than through consumer access. The law sets a December 31, 2027 deadline for the program, and the Department of Health has said it aims to enroll its first patients by the end of 2026. Producer applications opened in August 2026, and a buildout and inspection period is expected before treatment begins. Enacting a law does not mean services are already available. [13, 14]
Pennsylvania, New Jersey, and Florida: Of the states where Clarity MindCare practices, only Oregon has a regulated psilocybin services program. Pennsylvania and Florida do not offer legal access outside approved research. New Jersey lawmakers have pursued a hospital-based psilocybin research pilot program, not a public service framework like Oregon's.
Despite these state-level developments, psilocybin remains a Schedule I controlled substance under federal law and is not FDA-approved for treating depression, PTSD, or other psychiatric disorders. The FDA granted breakthrough therapy designation to Compass's COMP360 for treatment-resistant depression in 2018 and to Usona's psilocybin for major depressive disorder in 2019. A breakthrough therapy designation expedites development and review; it is not approval. [11, 15]
State authorization and FDA approval answer different questions. One establishes a state legal framework for access. The other requires evidence that a treatment meets federal regulatory standards for safety and effectiveness for a particular indication. If the FDA approves a psilocybin medicine, that approval will apply to a specific product and condition and will be separate from the state programs described above.
Where Psychedelic Integration Fits
As interest in psychedelics grows, so does the importance of understanding what happens after a psychedelic experience.
An experience may bring forward difficult emotions, memories, changes in perspective, or questions about relationships and personal values. Psychedelic integration provides an opportunity to explore these experiences in a therapeutic setting and consider how they relate to everyday life.
Integration does not involve administering psychedelic substances. It focuses on helping individuals process their experiences, make sense of what emerged, and approach any resulting changes thoughtfully.
Although integration is commonly included in psychedelic-assisted treatment protocols, research has not yet clearly established which integration approaches are most effective or how much they independently contribute to treatment outcomes. The trials discussed here evaluate psilocybin with support, rather than proving the independent benefit of a particular integration method.
For more on the period after an experience, read After a Psilocybin Session: What’s Normal, What Helps, and When to Reach Out.
A Promising Field That Still Needs Better Evidence
Psilocybin research has advanced considerably over the past decade. We now have randomized clinical trials, including two Phase 3 trials, suggesting potential benefits for depression, including in people who have not responded adequately to conventional treatments.
At the same time, the limitations are substantial. Blinding remains difficult, several key results have not yet been fully published, long-term safety data are incomplete, and the role of accompanying psychological support is not fully understood.
The growing availability of state-regulated psilocybin services should not be confused with scientific consensus that psilocybin is an established psychiatric treatment. An FDA approval, if it comes, would answer a narrower question about one product for one condition, and many clinical questions would remain. There is reason to take the research seriously, and equally good reason to continue examining it critically.
For now, a responsible approach is to recognize psilocybin's potential while being clear about what the evidence has and has not demonstrated.
At Clarity MindCare, psychedelic integration focuses on processing a prior experience. It does not include administering or prescribing psychedelics. Integration sessions are available by secure video for adults in Pennsylvania, New Jersey, Florida and Oregon.
Research and Legal Sources
Griffiths RR, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology. Read the study.
Ross S, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. Journal of Psychopharmacology. Read the study.
Carhart-Harris RL, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. Read the study.
Carhart-Harris R, et al. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. Read the study.
Goodwin GM, et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. Read the study.
Raison CL, et al. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA. Read the study.
Compass Pathways. (2026, July 7). Compass Pathways announces six-month data from second Phase 3 trial confirming rapid and durable profile [Press release]. Read the announcement.
Compass Pathways. (2026, August 5). Second quarter and first half 2026 financial results and business highlights [Press release]. Read the release.
Foley & Lardner LLP. (2026, April). Psychedelics and the executive order: From Schedule I to treatment priority. Read the analysis.
Yngwe H, et al. (2026). Short-term and late-term effects of psilocybin on symptoms in major depression: A randomized clinical trial. JAMA Network Open. Read the Swedish study.
Oregon Health Authority. What are psilocybin services?
Colorado Natural Medicine Division. Regulated services and unlawful activities.
New Mexico Department of Health. Medical Psilocybin Program and program FAQ.
Source NM. (2026, August 27). New Mexico psilocybin program opens permitting applications for psychedelic mushroom producers. Read the article.
Walter KL. (2026). What Is Psilocybin? JAMA. Read the article.
This article is for educational purposes and does not constitute individualized medical advice. Psilocybin is not an FDA-approved psychiatric treatment. State laws, federal regulatory status, and program availability may change.
